Proactive research analyst Daniel Appiah presents his report on London-listed Open Orphan PLC (AIM:ORPH, OTC:OPORF).
Open Orphan is a leader in human respiratory disease and infectious disease challenge clinical studies which are now becoming more commonly used to fast-track drug development.
The company has so far developed challenge protocols for nine different infections/conditions.